Bullous Pemphigoid Clinical Trial
Official title:
Prevalence and Clinical Severity of Autoimmune Blistering Diseases
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
The disease severity instruments for pemphigus and BP, the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), respectively, have the potential to capture changes in all grades of disease activity, including mild disease, and therefore represent a substantial improvement over simple lesion counts or measurements of affected body surface area. However, full validation of the PDAI and BPDAI for use in clinical trials will require additional and more extensive measurements that will enable us to classify patients correctly by disease severity and be able to define the minimal change in score that is clinically significant. This database study will compare the Pemphigus Disease Area and Severity Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI) against other disease severity measures, including the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and a physician's global assessment. Additionally, patients will be asked to rate their overall disease severity using a visual analogue scale, the patient's global assessment. Participants will also have the option to donate blood samples to our AIBD blood bank for immunologic and pathophysiologic studies. The purpose of this database study will also be to evaluate quality of life (QoL) measures and correlate these QoL measures with disease severity in patients with pemphigus and BP. QoL is an important and independent component of disease impact on patients. This database study will use the following QoL measures: the SF-36, which is a nonspecific QoL measure; the Skindez-29 and the Dermatology Life Quality Index (DLQI), which are dermatology-specific instruments; the Autoimmune Bullous Disease Quality of Life (ABQOL) and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires, which are AIBD-specific tools. The results will be utilized in planning future clinical studies. The AIBD study will be conducted only at Penn at this time. Data from the study will be entered into a password protected, web-based database that is used only at Penn. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03286582 -
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT02837965 -
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
|
||
| Recruiting |
NCT03636763 -
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
|
||
| Recruiting |
NCT00802243 -
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT05649579 -
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
|
||
| Active, not recruiting |
NCT04206553 -
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
|
Phase 2/Phase 3 | |
| Completed |
NCT00431119 -
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT04563923 -
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
|
Phase 2 | |
| Completed |
NCT03320798 -
Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
|
N/A | |
| Completed |
NCT03272958 -
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
|
||
| Completed |
NCT02883894 -
Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid
|
N/A | |
| Completed |
NCT00809822 -
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
|
Phase 2 | |
| Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
| Withdrawn |
NCT05061771 -
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
|
Phase 3 | |
| Not yet recruiting |
NCT04128176 -
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
|
Phase 3 | |
| Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
| Terminated |
NCT04612790 -
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
|
Phase 3 | |
| Recruiting |
NCT05681481 -
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
|
Phase 3 | |
| Completed |
NCT00286325 -
Rituximab in the Treatment of Patients With Bullous Pemphigoid
|
Phase 1/Phase 2 | |
| Completed |
NCT04728854 -
Telederm and Bullous Pemphigoid
|